EMAIL THIS PAGE TO A FRIEND

Nature communications

Lansoprazole is an antituberculous prodrug targeting cytochrome bc1.


PMID 26158909

Abstract

Better antibiotics capable of killing multi-drug-resistant Mycobacterium tuberculosis are urgently needed. Despite extensive drug discovery efforts, only a few promising candidates are on the horizon and alternative screening protocols are required. Here, by testing a panel of FDA-approved drugs in a host cell-based assay, we show that the blockbuster drug lansoprazole (Prevacid), a gastric proton-pump inhibitor, has intracellular activity against M. tuberculosis. Ex vivo pharmacokinetics and target identification studies reveal that lansoprazole kills M. tuberculosis by targeting its cytochrome bc1 complex through intracellular sulfoxide reduction to lansoprazole sulfide. This novel class of cytochrome bc1 inhibitors is highly active against drug-resistant clinical isolates and spares the human H(+)K(+)-ATPase thus providing excellent opportunities for targeting the major pathogen M. tuberculosis. Our finding provides proof of concept for hit expansion by metabolic activation, a powerful tool for antibiotic screens.

Related Materials

Product #

Image

Description

Molecular Formula

Add to Cart

O104
Omeprazole, solid
C17H19N3O3S
424455
Resorufin, Dye content 95 %
C12H7NO3
73144
Resorufin, 95%
C12H7NO3